Immunogenic composition of a homogeneous live attenuated human rotavirus population
AssigneeGlaxosmithkline Biologicals SA
InventorsBrigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Georges Thiry, Vincent Vande Velde
Life of this patent
Estimating the term…
Abstract
The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.
Claims24
An immunogenic composition comprising a live attenuated human rotavirus population admixed with a suitable pharmaceutical carrier or adjuvant, wherein the rotavirus population comprises a single variant comprising one or both of:
- a nucleic acid comprising a VP4 polynucleotide sequence comprising an adenine (A) at position 788;
- an adenine (A) at position 802;
- and a thymine (T) at position 501, relative to the start codon, and
- a nucleic acid comprising a VP7 polynucleotide sequence comprising a thymine (T) at position 605, an adenine (A) at position 897, and an adenine (A) at position 108, relative to the start codon.
A vaccine composition comprising a live attenuated rotavirus population designated as P43 that was serially passaged in cell culture, and is deposited under accession number ECACC 99081301.
Dependencies are inferred from the claim text.